11 Best Guru Stocks to Buy According to Wall Street Analysts

Page 7 of 10

4. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Number of Hedge Fund Holders: 44

Average Upside Potential: 132.43%

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a biopharmaceutical company that develops treatments for diseases with limited options. The company’s product pipeline is focused on geographic atrophy and rare kidney and transplant-related conditions. APLS is one of the best Guru stocks to invest in.

On March 3, Raymond James analyst Steven Seedhouse reiterated a Strong Buy rating on  Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) but trimmed the price target from $78 to $75. Despite expecting a slowdown in early 2025 due to Medicare paperwork, bad weather, and more product samples being used, the company sees strong growth ahead, supported by a 97% revenue boost over the past year and a healthy financial cushion. Apellis is especially optimistic about Syfovre, noting its flexible dosing schedule and strong backing from major insurers like Aetna. Syfovre could help Apellis grow its share in a competitive market that it has tapped into about 10% for now.

In the fourth quarter of 2024, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) earned $212.5 million in total revenue, driven by strong US sales of Syfovre and Empaveli, along with earnings from its Sobi partnership. The company also made progress in cutting its losses, with net losses dropping to $36.4 million for the quarter and $197.9 million for the year. With over $411 million in cash, Apellis is confident that its current financial position and product revenue will carry it through to profitability.

According to Insider Monkey’s fourth quarter database, 44 hedge funds were long Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), compared to 35 funds in the earlier quarter. Kurt Von Emster’s VenBio Select Advisor was the largest stakeholder of the company, with 12.2 million shares valued at $390 million.

Page 7 of 10